Optimal Dosage and Safety of Remimazolam Tosilate for Sedation in Patients on Mechanical Ventilation Admitted to ICU after Surgery

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100043752

Enrollment

Unknown

Registered

2021-02-27

Start date

2021-06-01

Completion date

Unknown

Last updated

2021-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients on mechanical ventilation admitted to ICU after surgery

Interventions

1:Intravenous administration of Remimazolam Tosilate

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. 18 years old <= age <= 60 years old; 2. The patient or his/her family agrees to participate in this study.

Exclusion criteria

Exclusion criteria: 1. Allergic to Remimazolam Tosilate; 2. Patients with acute Angle glaucoma, myasthenia gravis and coma (GCS 8 points after anesthesia); 3. Patients with uncorrected hemorrhagic or cardiogenic shock; 4. BMI 35 kg/m2; 5. Alcohol dependence, mental illness or severe cognitive impairment; 6. Pregnancy or lactation; 7. Poor compliance.

Design outcomes

Primary

Measure	Time frame
Single intravenous injection dose of Remimazolam Tosilate;Dose of Remimazolam Tosilate by continuous intravenous pump;	—

Secondary

Measure	Time frame
Vital signs;APACHE II score;SOFA score;GCS score;Blood routine examination;Liver and kidney's function and electrolyte metabolize;C-reactive protein;Blood coagulation function;Myocardial enzyme;Arterial blood gas analysis;Electrocardiogram;	—

Countries

China

Contacts

Public ContactShiying Yuan

Huazhong University of Science and Technology

yuan_shiying@163.com+86 13995646372

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026